These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25175006)

  • 1. Long term retention of retigabine in a cohort of people with drug resistant epilepsy.
    Wehner T; Chinnasami S; Novy J; Bell GS; Duncan JS; Sander JW
    Seizure; 2014 Nov; 23(10):878-81. PubMed ID: 25175006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel design for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical development.
    Sachdeo R; Partiot A; Biton V; Rosenfeld WE; Nohria V; Tompson D; DeRossett S; Porter RJ
    Int J Clin Pharmacol Ther; 2014 Jun; 52(6):509-18. PubMed ID: 24755135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: a single centre evaluation.
    Novy J; Bartolini E; Bell GS; Duncan JS; Sander JW
    Epilepsy Res; 2013 Sep; 106(1-2):250-6. PubMed ID: 23796862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive retigabine in refractory focal epilepsy: Postmarketing experience at four tertiary epilepsy care centers in Germany.
    Nass RD; Kurth C; Kull A; Graf W; Kasper B; Hamer HM; Strzelczyk A; Elger CE; Steinhoff BJ; Surges R; Rosenow F
    Epilepsy Behav; 2016 Mar; 56():54-8. PubMed ID: 26828693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retigabine for partial onset seizures.
    Rheims S; Ryvlin P
    Expert Rev Neurother; 2012 May; 12(5):509-17. PubMed ID: 22550979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective evaluation of retigabine in patients with cognitive impairment with highly drug-resistant epilepsy.
    Huber B; Bocchicchio M
    Epilepsy Behav; 2015 Mar; 44():234-7. PubMed ID: 25836054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.
    French JA; Abou-Khalil BW; Leroy RF; Yacubian EM; Shin P; Hall S; Mansbach H; Nohria V;
    Neurology; 2011 May; 76(18):1555-63. PubMed ID: 21451152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long-term retention of zonisamide in a large cohort of people with epilepsy at a tertiary referral centre.
    Catarino CB; Bartolini E; Bell GS; Yuen AW; Duncan JS; Sander JW
    Epilepsy Res; 2011 Sep; 96(1-2):39-44. PubMed ID: 21601427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of retigabine/ezogabine as adjunctive therapy in adult Asian patients with drug-resistant partial-onset seizures: A randomized, placebo-controlled Phase III study.
    Lim KS; Lotay N; White R; Kwan P
    Epilepsy Behav; 2016 Aug; 61():224-230. PubMed ID: 27376872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy.
    Brodie MJ; Lerche H; Gil-Nagel A; Elger C; Hall S; Shin P; Nohria V; Mansbach H;
    Neurology; 2010 Nov; 75(20):1817-24. PubMed ID: 20944074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use.
    Large CH; Sokal DM; Nehlig A; Gunthorpe MJ; Sankar R; Crean CS; Vanlandingham KE; White HS
    Epilepsia; 2012 Mar; 53(3):425-36. PubMed ID: 22221318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison.
    Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
    Seizure; 2008 Jan; 17(1):19-26. PubMed ID: 17618131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials.
    Porter RJ; Burdette DE; Gil-Nagel A; Hall ST; White R; Shaikh S; DeRossett SE
    Epilepsy Res; 2012 Aug; 101(1-2):103-12. PubMed ID: 22512894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal.
    Craig D; Rice S; Paton F; Fox D; Woolacott N
    Pharmacoeconomics; 2013 Feb; 31(2):101-10. PubMed ID: 23341194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
    Gunthorpe MJ; Large CH; Sankar R
    Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures.
    Biton V; Gil-Nagel A; Brodie MJ; Derossett SE; Nohria V
    Epilepsy Res; 2013 Nov; 107(1-2):138-45. PubMed ID: 24094693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
    Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF
    Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.
    Orhan G; Wuttke TV; Nies AT; Schwab M; Lerche H
    Expert Opin Pharmacother; 2012 Aug; 13(12):1807-16. PubMed ID: 22783830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison.
    Martyn-St James M; Glanville J; McCool R; Duffy S; Cooper J; Hugel P; Lane PW
    Seizure; 2012 Nov; 21(9):665-78. PubMed ID: 22902288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs.
    Groth A; Wilke T; Borghs S; Gille P; Joeres L
    Ger Med Sci; 2017; 15():Doc09. PubMed ID: 28638313
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.